Detailed description page of THPdb

Details of Th1125 which contains 13 entries.

Entry 1
(1) Primary information
ID 1583
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target Tumor necrosis factor
Information of corresponding available drug in the market
Brand Name Simponi Injection
Company N.A.
Brand Discription SIMPONI (golimumab) is a human IgG1Îº monoclonal antibody specific for human tumor necrosis factor alpha (TNFÎ±) that exhibits multiple glycoforms with molecular masses of approximately 150 to 151 kilodaltons. SIMPONI was created using genetically engineered mice immunized with human TNF, resulting in an antibody with human-derived antibody variable and constant regions. SIMPONI is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses. The SIMPONI drug product is a sterile solution of the golimumab antibody supplied as either a single dose prefilled syringe (with a passive needle safety guard) or a single dose prefilled autoinjector. The Type 1 glass syringe has a coated stopper. The fixed stainless steel needle (5 bevel, 27G, half-inch) is covered with a needle shield to prevent leakage of the solution through the needle and to protect the needle during handling to subcutaneous administration. The needle shield is made of a dry natural rubber containing latex.
Prescribed for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis
Chemical Name N.A.
Formulation pH of approximately 5.5. SIMPONI is provided in two strengths: 50 mg of the golimumab antibody in 0.5 mL of solution and 100 mg of the golimumab antibody in 1 mL of solution. In the 50 mg strength, 0.5 mL of SIMPONI contains 50 mg of the golimumab antibody, 0.44 mg of L-histidine and L-histidine monohydrochloride monohydrate, 20.5 mg of sorbitol, 0.08 mg of polysorbate 80, and Water for Injection. In the 100 mg strength, 1 mL of SIMPONI contains 100 mg of the golimumab antibody, 0.87 mg of L-histidine and L-histidine monohydrochloride monohydrate, 41.0 mg of sorbitol, 0.15 mg of polysorbate 80, and Water for Injection.
Physcial Appearance The solution is clear to slightly opalescent, colorless to light yellow
Route of Administration Subcutaneous
Recommended Dosage 50 mg once a month
Contraindication N.A.
Side Effects sepsis, alanine aminotransferase, aspartate aminotransferase, tuberculosis, anemia
Useful Link http://www.rxlist.com/simponi-drug.htm http://www.simponi.com/ http://www.drugs.com/simponi.html
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 2
(2) Primary information
ID 1584
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Simponi Aria
Company N.A.
Brand Discription SIMPONI ARIA (golimumab) is a human IgG1k monoclonal antibody specific for human tumor necrosis factor alpha (TNFÎ±) that exhibits multiple glycoforms with molecular masses of approximately 150 to 151 kilodaltons. SIMPONI ARIA was created using genetically engineered mice immunized with human TNF, resulting in an antibody with human-derived antibody variable and constant regions. SIMPONI ARIA is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses.
Prescribed for rheumatoid arthritis.
Chemical Name N.A.
Formulation SIMPONI ARIA does not contain preservatives, natural rubber or latex. The solution is colorless to light yellow with a pH of approximately 5.5. Each 4 mL vial of SIMPONI ARIA contains 50 mg golimumab, 9.5 mM histidine, 4.5% (w/v) sorbitol, and 0.015% (w/v) polysorbate 80.
Physcial Appearance The SIMPONI ARIA drug product is a sterile concentrated solution of the golimumab antibody supplied in a 4 mL glass vial for Intravenous infusion.
Route of Administration Intravenous infusion
Recommended Dosage 2 mg per kg
Contraindication N.A.
Side Effects sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections, Malignancies, Liver Enzyme Elevations, Autoimmune Disorders And Autoantibodies
Useful Link http://www.rxlist.com/simponi-aria-drug.htm https://www.simponiaria.com/ http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362202.pdf
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 3
(3) Primary information
ID 1585
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 4
(4) Primary information
ID 1586
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 5
(5) Primary information
ID 1587
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 6
(6) Primary information
ID 1588
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 7
(7) Primary information
ID 1589
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 8
(8) Primary information
ID 1590
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 9
(9) Primary information
ID 1591
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 10
(10) Primary information
ID 1592
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 11
(11) Primary information
ID 1593
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 12
(12) Primary information
ID 1594
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

Entry 13
(13) Primary information
ID 1595
ThPP ID Th1125
Therapeutic Peptide/Protein Name Golimumab
Sequence N.A. view full sequnce in fasta
Functional Classification IIb
Molecular Weight 146943.1937
Chemical Formula C6530H10068N1752O2026S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life About 2 weeks
Description Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism The metabolism of golimumab has yet to be determined.
Absorption After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link N.A.
PubMed ID 25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure N.A.

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

(1) Primary information
Entry 1
ID	1583
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	Tumor necrosis factor
Information of corresponding available drug in the market
Brand Name	Simponi Injection
Company	N.A.
Brand Discription	SIMPONI (golimumab) is a human IgG1Îº monoclonal antibody specific for human tumor necrosis factor alpha (TNFÎ±) that exhibits multiple glycoforms with molecular masses of approximately 150 to 151 kilodaltons. SIMPONI was created using genetically engineered mice immunized with human TNF, resulting in an antibody with human-derived antibody variable and constant regions. SIMPONI is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses. The SIMPONI drug product is a sterile solution of the golimumab antibody supplied as either a single dose prefilled syringe (with a passive needle safety guard) or a single dose prefilled autoinjector. The Type 1 glass syringe has a coated stopper. The fixed stainless steel needle (5 bevel, 27G, half-inch) is covered with a needle shield to prevent leakage of the solution through the needle and to protect the needle during handling to subcutaneous administration. The needle shield is made of a dry natural rubber containing latex.
Prescribed for	Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis
Chemical Name	N.A.
Formulation	pH of approximately 5.5. SIMPONI is provided in two strengths: 50 mg of the golimumab antibody in 0.5 mL of solution and 100 mg of the golimumab antibody in 1 mL of solution. In the 50 mg strength, 0.5 mL of SIMPONI contains 50 mg of the golimumab antibody, 0.44 mg of L-histidine and L-histidine monohydrochloride monohydrate, 20.5 mg of sorbitol, 0.08 mg of polysorbate 80, and Water for Injection. In the 100 mg strength, 1 mL of SIMPONI contains 100 mg of the golimumab antibody, 0.87 mg of L-histidine and L-histidine monohydrochloride monohydrate, 41.0 mg of sorbitol, 0.15 mg of polysorbate 80, and Water for Injection.
Physcial Appearance	The solution is clear to slightly opalescent, colorless to light yellow
Route of Administration	Subcutaneous
Recommended Dosage	50 mg once a month
Contraindication	N.A.
Side Effects	sepsis, alanine aminotransferase, aspartate aminotransferase, tuberculosis, anemia
Useful Link	http://www.rxlist.com/simponi-drug.htm http://www.simponi.com/ http://www.drugs.com/simponi.html
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(2) Primary information
Entry 2
ID	1584
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Simponi Aria
Company	N.A.
Brand Discription	SIMPONI ARIA (golimumab) is a human IgG1k monoclonal antibody specific for human tumor necrosis factor alpha (TNFÎ±) that exhibits multiple glycoforms with molecular masses of approximately 150 to 151 kilodaltons. SIMPONI ARIA was created using genetically engineered mice immunized with human TNF, resulting in an antibody with human-derived antibody variable and constant regions. SIMPONI ARIA is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses.
Prescribed for	rheumatoid arthritis.
Chemical Name	N.A.
Formulation	SIMPONI ARIA does not contain preservatives, natural rubber or latex. The solution is colorless to light yellow with a pH of approximately 5.5. Each 4 mL vial of SIMPONI ARIA contains 50 mg golimumab, 9.5 mM histidine, 4.5% (w/v) sorbitol, and 0.015% (w/v) polysorbate 80.
Physcial Appearance	The SIMPONI ARIA drug product is a sterile concentrated solution of the golimumab antibody supplied in a 4 mL glass vial for Intravenous infusion.
Route of Administration	Intravenous infusion
Recommended Dosage	2 mg per kg
Contraindication	N.A.
Side Effects	sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections, Malignancies, Liver Enzyme Elevations, Autoimmune Disorders And Autoantibodies
Useful Link	http://www.rxlist.com/simponi-aria-drug.htm https://www.simponiaria.com/ http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362202.pdf
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(3) Primary information
Entry 3
ID	1585
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(4) Primary information
Entry 4
ID	1586
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(5) Primary information
Entry 5
ID	1587
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(6) Primary information
Entry 6
ID	1588
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(7) Primary information
Entry 7
ID	1589
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(8) Primary information
Entry 8
ID	1590
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(9) Primary information
Entry 9
ID	1591
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(10) Primary information
Entry 10
ID	1592
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(11) Primary information
Entry 11
ID	1593
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(12) Primary information
Entry 12
ID	1594
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.

(13) Primary information
Entry 13
ID	1595
ThPP ID	Th1125
Therapeutic Peptide/Protein Name	Golimumab
Sequence	N.A. view full sequnce in fasta
Functional Classification	IIb
Molecular Weight	146943.1937
Chemical Formula	C6530H10068N1752O2026S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	About 2 weeks
Description	Human IgG1Ò› monoclonal antibody derived from immunizing genetically engineered mice with human TNFÎ±. It binds and inhibits soluble and transmembrane human TNFÎ±. Increased TNFÎ± is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Indication/Disease	Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
Pharmacodynamics	Golimumab inhibits the activity of the cytokine, tumor necrosis factor alpha (TNFÎ±). In areas such as the joints and blood, increased TNFÎ±is associated with chronic inflammation seen in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Thus golimumab decreases the inflammation in these conditions. Concerning ulcerative colitis, the physiological effects of golimumab has yet to be determined.
Mechanism of Action	As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFÎ±. Inhibition of TNFÎ± prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
Toxicity	The FDA label includes a black box warning of serious infections and malignancy. Specifically there have been hospitalizations or death from infections such as bacterial sepsis, tuberculosis (TB), and invasive fungal (histoplasmosis) and other opportunistic infections. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.
Metabolism	The metabolism of golimumab has yet to be determined.
Absorption	After subcutaneous administration, golimumab can achieve maximum serum concentrations in 2 to 6 days and has an approximate bioavailability of 53%. In healthy volunteers, the maximum average concentration reached was 3.2 Â± 1.4 Î¼g/mL.
Volume of Distribution	After IV administration, golimumab has a volume of distribution of about 58 to 126 mL/kg. This means that golimumab stays mostly in the circulatory system.
Clearance	After one IV dose of golimumab, the systemic clearance was about 4.9 to 6.7 mL/day/kg.
Categories	Antipsoriatic Agents and Monoclonal antibodies and TNF inhibitor
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	N.A.
PubMed ID	25629655, 25627338, 25623393, 25602858, 25547737, 23770005, 19489653
3-D Structure	N.A.